116437-42-4Relevant articles and documents
DNA-damaging steroidal alkaloids from Eclipta alba from the suriname rainforest
Abdel-Kader, Maged S.,Bahler, Brian D.,Malone, Stan,Werkhoven, Marga C. M.,Van Troon, Frits,David,Wisse, Jan H.,Bursuker, Isia,Neddermann, Kim M.,Mamber, Stephen W.,Kingston, David G. I.
, p. 1202 - 1208 (1998)
Bioassay-guided fractionation of the MeOH extract of Eclipta alba using three yeast strains (1138, 1140, and 1353) resulted in the isolation of eight bioactive steroidal alkaloids (1-8), six of which are reported for the first time from nature. The major alkaloid was identified as (20S)(25S)-22,26- imino-cholesta-5,22(N)-dien-3β-ol (verazine, 3), while the new alkaloids were identified as 20-epi-3-dehydroxy-3-oxo-5,6-dihydro-4,5-dehydroyerazine (1), ecliptalbine [(20R)-20-pyridyl-cholesta-5-ene-3β,23-diol] (4), (20R)- 4β-hydroxyverazine (5), 4β-hydroxyverazine (6), (20R)-25β-hydroxyverazine (7), and 25β-hydroxyverazine (8). Ecliptalbine (4), in which the 22,26- imino ring of verazine was replaced by a 3-hydroxypyridine moiety, had comparable bioactivity to verazine in these assays, while a second alkaloid (8) showed good activity against Candida albicans. All the alkaloids showed weak cytotoxicity against the M-109 cell line.
Enantioselective Direct Synthesis of Free Cyclic Amines via Intramolecular Reductive Amination
Zhang, Ying,Yan, Qiaozhi,Zi, Guofu,Hou, Guohua
supporting information, p. 4215 - 4218 (2017/08/23)
Chiral cyclic amines can be prepared via intramolecular reductive amination of N-Boc-protected amino ketones in a one-pot process. With the complex of iridium and f-spiroPhos as the catalyst, a range of N-Boc-protected amino ketones are smoothly transformed into chiral cyclic free amines in high yields and excellent enantioselectivities (up to 97% ee). Moreover, this method can also be successfully applied to the synthesis of a κ-opioid receptor selective antagonist, (S)-1.
PYRIDO PYRIMIDINES
-
Page/Page column 105, (2012/07/28)
Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.